Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients

Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories

(2010) M. Fiegl et al.   ANNALS OF ONCOLOGY

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

(2009) Raman Sood et al.   AMERICAN JOURNAL OF HEMATOLOGY

Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non–Small-Cell Lung Cancer

(2009) Egbert F. Smit et al.   JOURNAL OF CLINICAL ONCOLOGY

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

(2009) Stephan Stilgenbauer et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study

(2009) A Cortelezzi et al.   LEUKEMIA

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia

(2009) A Österborg et al.   LEUKEMIA

Treatment of elderly patients with chronic lymphocytic leukemia

(2009) Barbara Eichhorst et al.   LEUKEMIA & LYMPHOMA

Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer

(2008) T.T. NGUYEN et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Alemtuzumab in clinical practice: A British Columbia experience

(2008) David Hui et al.   LEUKEMIA & LYMPHOMA